Efficacy of tofacitinib in treatment of alopecia universalis in two patients

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 8, 2016, Pages 1373-1378

  Gupta, A K ^a,b   Carviel, J L ^b   Abramovits, W ^c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Dermatology Treatment and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; COLECALCIFEROL; CORTICOSTEROID; MINOXIDIL; MULTIVITAMIN; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TOFACITINIB; TRIAMCINOLONE ACETONIDE;

ADULT; ALOPECIA; ALOPECIA UNIVERSALIS; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; EYEBROW; EYELASH; HAIR GROWTH; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; SCALP HAIR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84987910753     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13598     Document Type: Article

References (70)

1. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515–1525.
2. McElwee KJ, Gilhar A, Tobin DJ et al. What causes alopecia areata? Exp Dermatol 2013; 22: 609–626.
3. Peters EMJ, Liotiri S, Bodó E et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol 2007; 171: 1872–1886.
4. Van der Steen P, Traupe H, Happle R, Boezeman J, Sträter R, Hamm H. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol 1992; 72: 373–375.
5. McDonagh AJG, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002; 27: 405–409.
6. Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new findings, new treatments. J Dermatol Sci 2015; 78: 11–20.
7. Barahmani N, Schabath MB, Duvic M. National Alopecia Areata Registry. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009; 61: 581–591.
8. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 2013; 149: 789–794.
9. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev 2008; 2: CD004413.
10. Abramovits W, Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed 2006; 5: 177–181.
11. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014; 134: 1149–1152.
12. Billingham RE, Silvers WK. A biologist's reflections on dermatology. J Invest Dermatol 1971; 57: 227–240.
13. Hong S, Van Kaer L. Immune privilege: keeping an eye on natural killer T cells. J Exp Med 1999; 190: 1197–1200.
14. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002; 22: 13–46.
15. Ito T, Ito N, Saathoff M et al. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 2005; 125: 1139–1148.
16. Ito T, Meyer KC, Ito N, Paus R. Immune privilege and the skin. Curr Dir Autoimmun 2008; 10: 27–52.
17. Kern S, Robertson SA, Mau VJ, Maddocks S. Cytokine secretion by macrophages in the rat testis. Biol Reprod 1995; 53: 1407–1416.
18. O'Bryan MK, Gerdprasert O, Nikolic-Paterson DJ et al. Cytokine profiles in the testes of rats treated with lipopolysaccharide reveal localized suppression of inflammatory responses. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1744–R1755.
19. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000; 18: 367–391.
20. Erlebacher A. Why isn't the fetus rejected? Curr Opin Immunol 2001; 13: 590–593.
21. Paus R, Nickoloff BJ, Ito T. A “hairy” privilege. Trends Immunol 2005; 26: 32–40.
22. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 2004; 164: 623–634.
23. Meyer KC, Klatte JE, Dinh HV et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008; 159: 1077–1085.
24. Kang H, Wu W-Y, Lo BKK et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 2010; 130: 2677–2680.
25. Ito T, Tokura Y. Alopecia areata triggered or exacerbated by swine flu virus infection. J Dermatol 2012; 39: 863–864.
26. Kinori M, Bertolini M, Funk W et al. Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-γ-induced collapse of human hair follicle immune privilege. Exp Dermatol 2012; 21: 223–226.
27. Christoph T, Müller-Röver S, Audring H et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000; 142: 862–873.
28. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007; 117: 2019–2027.
29. Bertolini M, Gilhar A, Paus R. Alopecia areata as a model for T cell-dependent autoimmune diseases. Exp Dermatol 2012; 21: 477–479.
30. Sugawara K, Bíró T, Tsuruta D et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol 2012; 129: 726–738.e8.
31. Harrist TJ, Ruiter DJ, Mihm MC, Bhan AK. Distribution of major histocompatibility antigens in normal skin. Br J Dermatol 1983; 109: 623–633.
32. Paus R, van der Veen C, Eichmüller S et al. Generation and cyclic remodeling of the hair follicle immune system in mice. J Invest Dermatol 1998; 111: 7–18.
33. Foitzik K, Lindner G, Mueller-Roever S et al. Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J Off Publ Fed Am Soc Exp Biol 2000; 14: 752–760.
34. Napolitano G, Montani V, Giuliani C et al. Transforming growth factor-beta1 down-regulation of major histocompatibility complex class I in thyrocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription factors. Mol Endocrinol 2000; 14: 486–505.
35. Slominski A, Botchkareva NV, Botchkarev VA et al. Hair cycle-dependent production of ACTH in mouse skin. Biochim Biophys Acta 1998; 1448: 147–152.
36. Kono M, Nagata H, Umemura S, Kawana S, Osamura RY. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. FASEB J Off Publ Fed Am Soc Exp Biol 2001; 15: 2297–2299.
37. Saji M, Moriarty J, Ban T, Kohn LD, Singer DS. Hormonal regulation of major histocompatibility complex class I genes in rat thyroid FRTL-5 cells: thyroid-stimulating hormone induces a cAMP-mediated decrease in class I expression. Proc Natl Acad Sci U S A 1992; 89: 1944–1948.
38. Rückert R, Hofmann U, van der Veen C, Bulfone-Paus S, Paus R. MHC class I expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo. J Invest Dermatol 1998; 111: 25–30.
39. Rosenblum MD, Olasz EB, Yancey KB et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol 2004; 123: 880–887.
40. Rosenblum MD, Yancey KB, Olasz EB, Truitt RL. CD200, a “no danger” signal for hair follicles. J Dermatol Sci 2006; 41: 165–174.
41. Petukhova L, Duvic M, Hordinsky M et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466: 113–117.
42. Ito T, Ito N, Saatoff M et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008; 128: 1196–1206.
43. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998; 160: 5693–5696.
44. Xing L, Dai Z, Jabbari A et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043–1049.
45. Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234–4243.
46. Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol 2000; 164: 1643–1647.
47. Toyoda M, Makino T, Kagoura M, Morohashi M. Expression of neuropeptide-degrading enzymes in alopecia areata: an immunohistochemical study. Br J Dermatol 2001; 144: 46–54.
48. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993; 66: 541–554.
49. Witthuhn BA, Silvennoinen O, Miura O et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994; 370: 153–157.
50. Rodig SJ, Meraz MA, White JM et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373–383.
51. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875–878.
52. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273–287.
53. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127–132.
54. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513–526.
55. Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep 2012;4:5.
56. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293–322.
57. Ortiz-Ibáñez K, Alsina MM, Muñoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermo-Sifiliográficas 2013; 104: 304–310.
58. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32: 25–34.
59. Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother 2014; 15: 103–113.
60. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203: 127–142.
61. Adis Editorial. Tofacitinib. Drugs RD 2010;10:271–84.
62. Van Gurp EAFJ, Schoordijk-Verschoor W, Klepper M et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87: 79–86.
63. Buckley RH, Schiff RI, Schiff SE et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130: 378–387.
64. Conklyn M, Andresen C, Changelian P, Kudlacz E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8 + cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004; 76: 1248–1255.
65. Mackay-Wiggan J. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe alopecia areata, totalis and universalis [Internet]. [WWW document] 2014. URL http://clinicaltrials.gov/ct2/show/NCT02299290 (last accessed: Aug 25 2015).
66. Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med 2014; 20: 989–990.
67. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol JEADV 2014; 28: 192–203.
68. Ports WC, Khan S, Lan S et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169: 137–145.
69. Huang J-F, Yafawi R, Zhang M et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 2012; 119: e43–e50.
70. Fukuyama T, Ehling S, Cook E, Bäumer W. Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther 2015; 354: 394–405.